antiarrhythmic


Also found in: Dictionary, Thesaurus, Medical.

antiarrhythmic

[‚an·tē‚ā′rith·mik]
(medicine)
An agent that prevents or alleviates cardiac arrhythmia.
References in periodicals archive ?
Brinavess (vernakalant HCl, IV) is an antiarrhythmic drug that acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion.
Uwe Klein, Ph.D., VP of Biology at Numerate, will continue to serve as principal investigator and will lead discovery efforts for the programme titled 'Peripherally restricted ?2/?-1 subunit ligands that modulate CaV channel gating as novel antiarrhythmic drugs'.
Buch, who worked on the trial agrees, pointing out that both antiarrhythmic drugs and catheter ablation are reasonable options for older adults with A-fib, and the decision about whether to choose one of these treatments must be individualized for each patient.
A variety of antiarrhythmic medications (adenosine, amiodarone, verapamil, and metoprolol) also failed to control the tachyarrhythmia.
Those who had their AFl converted by antiarrhythmic drugs/cardioversion prior to their scheduled ablation procedure as well as patients whose electrocardiogram was not available on the day of the ablation were excluded from the analysis.
All enrolled patients had to have a history of being refractory to or intolerant of a beta-blocker or an antiarrhythmic drug.
It should be noted that, during the last 3 years, the patient underwent antiarrhythmic treatment with amiodarone, followed by propafenone and, since last year, 200 mg daily of flecainide.
To inhibit irregular electrical activities, antiarrhythmic drugs act by targeting the cardiomyocyte membrane ion channel, altering the conduction velocity, and repressing trigger activity.
Findings could lead to new efforts to better man-age AF by gender, including antiarrhythmic therapy and radiofrequency ablation, researchers write.
The hypertrophic cardiomyopathy therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (antiarrhythmic agents, anticoagulants, beta adrenergic blocking agents, and calcium channel blockers) and clinical pipeline analysis of phase 1, 2 and 3 drugs, and forecasts growth trends (CAGR% - 2015 to 2020).